Brief: Eagle Pharmaceuticals Submits Investigational New Drug Application To U.S. FDA For Cal02, A Drug Meant For The Treatment Of Severe Community-Acquired Bacterial Pneumonia
12/10/2022 11:59
Oct 12 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL
NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR
CAL02, A NOVEL FIRST-IN-CLASS BROAD-SPECTRUM ANTI-VIRULENCE
AGENT FOR THE TREATMENT OF SEVERE COMMUNITY-ACQUIRED BACTERIAL
PNEUMONIA
* INTERIM RESULTS EXPECTED APPROXIMATELY ONE YEAR AFTER
PATIENT
ENROLLMENT BEGINS
* PATIENT ENROLLMENT FOR CAL02 IS EXPECTED AS EARLY AS
BEGINNING
OF 2023
* BELIEVES CAL02 NEW DRUG APPLICATION FOR TREATMENT OF SCABP
MAY
QUALIFY FOR PRIORITY REVIEW
Source text for Eikon: ID:nGNX1FzvlJ
Further company coverage: EGRX.O
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq